The diagnostic and prognostic value of serum endocan in patients with cirrhotic cardiomyopathy
| Autor: | Radu Bogdan Mateescu, Cristian Baicus, Paul Bălănescu, Bianca Smarandache, Theodor Voiosu, Andrei Voiosu, Aurelia Rădoi, Ioana Daha |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2018 |
| Předmět: |
Liver Cirrhosis
Male medicine.medical_specialty Cirrhosis genetic structures Heart disease Population 030204 cardiovascular system & hematology Gastroenterology Cohort Studies 03 medical and health sciences Liver disease 0302 clinical medicine Internal medicine Medicine Humans echocardiography Decompensation education Aged education.field_of_study endocan haemodynamics business.industry Romania cirrhosis portal hypertension Middle Aged medicine.disease Prognosis RC31-1245 Cirrhotic cardiomyopathy follow-up studies Neoplasm Proteins nervous system cirrhotic cardiomyopathy Portal hypertension Biomarker (medicine) 030211 gastroenterology & hepatology Female Proteoglycans business Cardiomyopathies Biomarkers |
| Zdroj: | Romanian Journal of Internal Medicine, Vol 56, Iss 3, Pp 182-192 (2018) |
| Popis: | Background. We aimed to determine the relationship between endocan and cirrhotic cardiomyopathy. Materials and methods. Patients with liver cirrhosis and no heart disease were included in a prospective observational study with liver disease decompensation and death as primary outcomes. Results. 83 cirrhotic patients were included and 32 had cirrhotic cardiomyopathy. Endocan levels were significantly lower in patients with cirrhotic cardiomyopathy (5.6 vs. 7 ng/mL, p = 0.034). Endocan correlated with severity of cirrhosis, time to decompensation or death from liver disease (OR 4.5 95% CI 1.06-31.1). Conclusion. Endocan is a promising biomarker of severity of cirrhosis and may help in the diagnosis of cardiac dysfunction in this population. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|